Switch II pocket inhibitor allosterically freezes KRASG12Dnucleotide-binding site and arrests the GTPase cycle.

In simple terms

This study is like taking apart a car engine and showing how a new tool fits into one part and stops it from moving. It doesn't prove the tool fixes the whole car or makes it drive better—it just shows what happens inside that one piece.

Analysis score

0/ 0

Maximum 0 for a computational/algorithm study.

Where the score came from

Reporting0

Methodology0

Publication100

Statistical77

Study type (basis of the score)

Computational/Algorithm Study

Level 5 - Expert opinion

What’s the bottom line?

This study found a drug that locks a broken cancer protein (KRASG12D) in place so it can't turn on or off, stopping it from telling cells to grow nonstop.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5

StrongerWeaker

Expert Opinion

Level 5

0 / 100

Quality score

Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

1Yes—by freezing the protein, the drug stops the cancer signal at its source, which could shrink tumors, but the partial BRAF binding might let some signals sneak through.
2The drug binds 700 times tighter to the cancer version than the normal one, blocks all switching activity, and only weakly reduces interaction with the next protein in the chain (BRAF).

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data